Pharmaxis and Charlie Teo Foundation Identify Promising New Drug to Tackle Brain Cancer
3rd
May 21
Release Date: 03/05/2021 8:10am
Unique mechanism of drug action inhibits enzymes critical to tumour growth and survival
An Australian drug discovery will be the focus of a new study to tackle an aggressive and deadly form of brain cancer with a funding grant from the Charlie Teo Foundation. The drug, developed by Sydney-based research company Pharmaxis (ASX: PXS), will enter pre-clinical efficacy testing for glioblastoma (GBM), the most common form of brain cancer with an average survival of only 15 months from diagnosis.
Categories: News and Media